Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation

Stock Information for Achieve Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Achieve Life Sciences Inc.

Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.